RxDoctor Payments Data

James Slover, MD

Orthopedic Surgery · New York, NYNPI 1851355564

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $9,828 of the $12,746 with a category attached, or 77.1%. Amgen accounts for 88.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $11,744 and has fallen 99.7% since, to $36 in 2025.

$12,746in general payments, 2019–2025

Across 31 payments — averaging $411.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$11K
  • Zimmer Biomet$582
  • Medtronic$273
  • Smith+Nephew$210
  • Medical Device Business Services, Inc.$147
  • Stryker$124
  • plus $177 from 2 others
$5,771in research payments, 2019–2025

Across 9 payments — averaging $641.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Zimmer Biomet$6K

What the payments were for

  • Speaking & faculty fees$9,82877%
  • Travel & lodging$1,0488%
  • Food & beverage$1,86915%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,746 in reported general payments places this provider in the 85th percentile of 91 orthopedic surgery providers in New York.

See all orthopedic surgery providers in New York

Medicare billing

Part B allowed, 2024
$177,531
Medicare patients
398
Services billed
832

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Meloxicam37$57

Paid to pharmacies, not to this prescriber.

Other orthopedic surgery in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →